User profiles for Elena Fumagalli

Elena M. Fumagalli

- Verified email at uu.nl - Cited by 2971

Elena Fumagalli

- Verified email at uu.nl - Cited by 1360

Elena Fumagalli

- Verified email at incae.edu - Cited by 142

Obesity and socioeconomic status in developing countries: a systematic review

GD Dinsa, Y Goryakin, E Fumagalli… - Obesity …, 2012 - Wiley Online Library
We undertook a systematic review of studies assessing the association between socioeconomic
status (SES) and measured obesity in low‐ and middle‐income countries (defined by …

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience

…, S Bonvalot, P Schöffski, S Bauer, E Fumagalli… - Annals of surgical …, 2013 - Springer
Background Preoperative imatinib therapy of locally advanced GIST may facilitate resection
and decrease morbidity of the procedure. Methods We have pooled databases from 10 …

Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1

E Fumagalli, M Funicello, T Rauen, M Gobbi… - European journal of …, 2008 - Elsevier
Riluzole exerts a neuroprotective effect through different mechanisms, including action on
glutamatergic transmission. We investigated whether this drug affects glutamate transporter-…

Imatinib mesylate in chordoma

…, R Bertieri, R Bertulli, M Colecchia, E Fumagalli… - Cancer, 2004 - Wiley Online Library
BACKGROUND To the authors' knowledge, no effective medical therapy currently is available
for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐…

Outcome of patients with platelet-derived growth factor receptor alpha–mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era

PA Cassier, E Fumagalli, P Rutkowski, P Schöffski… - Clinical Cancer …, 2012 - AACR
Purpose: Platelet-derived growth factor receptor-alpha (PDGFRA) mutations are found in
approximately 5% to 7% of advanced gastrointestinal stromal tumors (GIST). We sought to …

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for …

…, S Sleijfer, JM Kerst, P Rutkowski, E Fumagalli… - 2017 - repository.icr.ac.uk
Purpose To report on the long-term results of a randomized trial comparing a standard dose
(400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally …

Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research …

…, P Rutkowski, P Hohenberger, E Fumagalli… - Journal of Clinical …, 2015 - ascopubs.org
Purpose In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no
further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI …

More than Machines: The Role of the Future Retail Salesperson in Enhancing the Customer Experience

A Pappas, E Fumagalli, M Rouziou, W Bolander - Journal of Retailing, 2023 - Elsevier
Retail sales has consistently faced threats by technology throughout history, with the recent
advent of Artificial Intelligence (AI) posing the most recent challenge. It is often said that …

From social capital to health–and back

L Rocco, E Fumagalli, M Suhrcke - Health economics, 2014 - Wiley Online Library
We assess the causal relationship between health and social capital, measured by
generalized trust, both at the individual and the community level. The paper contributes to the …

Changing the regulation for regulating the change: Innovation-driven regulatory developments for smart grids, smart metering and e-mobility in Italy

LL Schiavo, M Delfanti, E Fumagalli, V Olivieri - Energy policy, 2013 - Elsevier
For a long time considered as technologically mature, electric systems are now facing a
period of rapid evolution, inspired by climate change concerns. Several studies show that …